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A B S T R A C T
Familial atypical multiple mole melanoma (FAMMM) syndrome is a hereditary syndrome characterized by
multiple dysplastic nevi and melanoma. Patients with FAMMM may have a heterozygous, inactivating, patho-
genic germline variant in the CDKN2A gene, especially the NM_000077.4: c.225_243del19 (p.p75fs) variant, also
known as p16-Leiden variant. Patients with this variant are at high risk for developing melanomas and pancreatic
cancer due to somatic inactivation of the wild-type CDKN2A allele. The combination of an inactivating germline
CDKN2A mutation and somatic inactivation of the wild-type CDKN2A allele in the same cell results in tumor
formation. It has been suggested that carriers of a germline CDKN2A mutation are also at increased risk for
several other cancer types, including esophageal cancer. Here, we describe two unrelated patients with the p16-
Leiden variant who developed esophageal squamous cell cancer. Evidence of loss of the wild-type CDKN2A allele
was obtained in the tumor tissue of both patients indicating biallelic inactivation of p16 in the tumor cells. These
results suggest that these patients developed esophageal squamous cell cancer in the context of FAMMM syn-
drome.
1. Background
Tumor suppressor genes represent an important class of genes. Their
products either repress cell proliferation or promote apoptosis.
Therefore, inhibition of tumor suppressor genes can result in excessive
cell proliferation or diminished apoptosis and thereby drive oncogen-
esis (Sherr, 2004). An example of a tumor suppressor gene is CDKN2A,
which resides at locus 9p21. This gene encodes for two proteins
p16INK4a and p14ARF. These proteins are involved in the p16-re-
tinoblastoma and p14ARF-p53 pathways and promote G1 to S-phase
transition in the cell cycle, cell cycle arrest and apoptosis (Ruas and
Peters, 1998; Serrano et al., 1996; Sherr, 2001). Germline pathogenic
variants in CDKN2A are found in families with familial atypical mul-
tiple mole melanoma (FAMMM) syndrome, characterized by multiple
dysplastic nevi and melanoma (Lynch et al., 1981, 2002; Bartsch et al.,
2002; Smeds et al., 2002; Rulyak et al., 2003; Harinck et al., 2012; Zhen
et al., 2015). Apart from melanomas, pathogenic CDKN2A variants,
especially the NM_000077.4: c.225_243del19 (p.p75fs) variant (p16-
Leiden variant) also cause an increased pancreatic cancer risk. A
germline pathogenic CDKN2A variant is inherited in an autosomal
dominant way (with incomplete penetrance). For biallelic inactivation
of the CDKN2A gene and thus, the p16 tumor-suppressor protein, a
“second-genetic-hit” according to the two-hit hypothesis of Knudson is
necessary in the tumor (Knudson, 1971). In addition to melanoma and
pancreatic cancer, it has been suggested that patients with a pathogenic
CDKN2A variant could be at increased risk for other malignancies, such
as head and neck cancer and lung cancer (Bartsch et al., 2002; Bergman
et al., 1990; Goldstein et al., 1995; Vasen et al., 2000; Borg et al., 2000;
Middlebrooks et al., 2019). Here, we describe two patients with
FAMMM syndrome, a germline CDKN2A mutation (p16-Leiden variant)
and esophageal squamous cell carcinoma (ESCC) in whom detailed
genomic analysis was performed to study whether or not the esophageal
tumor developed in the context of FAMMM syndrome. Moreover, we
reviewed published reports on esophageal cancer in FAMMM syn-
drome.
https://doi.org/10.1016/j.ejmg.2020.103840
Received 26 September 2019; Received in revised form 10 December 2019; Accepted 5 January 2020
∗ Corresponding author. Department of Surgery, Erasmus MC – University Medical Center Rotterdam, Suite Na-2119, P.O. Box 2040, 3000, CA, Rotterdam, the
Netherlands.
E-mail address: b.vanderwilk@erasmusmc.nl (B.J. van der Wilk).
European Journal of Medical Genetics xxx (xxxx) xxxx
1769-7212/ © 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Please cite this article as: Berend J. van der Wilk, et al., European Journal of Medical Genetics, https://doi.org/10.1016/j.ejmg.2020.103840
2. Patients and methods
Written informed consent for analysis and publication was obtained
from both patients.
2.1. Patient one
A 51-year old man with ESCC was referred to Erasmus University
Medical Center, Rotterdam, the Netherlands. The patient has a medical
history of dysplastic nevi. Between age 28 and 51 he had developed six
melanomas in non-sun exposed areas. He had smoked cigarettes for
thirty years (one pack per three days), but had quit smoking three years
before diagnosis. He did not drink alcohol. His family history revealed
that his sister had multiple melanomas, his mother multiple melanomas
and pancreatic cancer, his aunt pancreatic cancer, his uncle lung
cancer, and his grandfather lung cancer (Fig. 1a). The patient, his sister,
his mother and his aunt were carriers of the p16-Leiden variant in the
CDKN2A gene, as had been determined previously.
After standard diagnostic work-up following endoscopy with his-
tological biopsies, consisting of endo-ultrasonography, thoracic and
abdominal CT and FDG-PET-CT, the patient was staged with cT3N1M0
ESCC. He was scheduled for neoadjuvant chemoradiotherapy, followed
by surgical resection (van Hagen et al., 2012). During surgery the tumor
appeared unresectable due to inﬁltration of the aorta. The patient re-
fused palliative chemotherapy and was referred for best supportive
care. He died six months later as a result of disease progression.
2.2. Patient two
A 58-year old female with ESCC was referred to Elisabeth –
Tweesteden Hospital in Tilburg, the Netherlands. She had developed
four melanomas between 32 and 52 years of age and ovarian cancer at
age 47. She used to drink alcohol daily for several years, but quit
drinking two years before the current diagnosis. She had never smoked.
The patient has two daughters and a son, of whom the two daughters
developed melanomas at age 13 and 21 years. Furthermore, two sisters
developed melanomas at age 28 and 49. Her mother developed and
died from breast cancer at age 53 and one uncle and two male cousins
developed melanomas (Fig. 1b). Both the patient herself and her oldest
daughter were carriers of the same p16-Leiden variant in CDKN2A, as
had been determined previously.
Standard diagnostic work-up after endoscopy with histologic biop-
sies consisted of endo-ultrasonography, thoracic and abdominal CT and
FDG-PET-CT and the patient was staged with cT3N0M0 ESCC. She was
scheduled for neoadjuvant chemoradiotherapy, followed by minimally
invasive esophagectomy; the tumor was microscopically radically re-
sected. Currently, patient is in good health and still in follow-up.
Fig. 1a. Family tree of the ﬁrst FAMMM patient in whom genomic LOH-analysis was performed (marked by an arrow) with four proven carriers of the p16-Leiden
variant in CDKN2A. Two additional members of the family had clinical features of FAMMM.
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2.3. Genomic analysis
From both patients, DNA was isolated from formalin ﬁxed an par-
aﬃn embedded (FFPE) tissue specimens. Tissue areas composed of
normal cells and of a high percentage (> 80%) of tumor cells were
manually microdissected from hematoxylin-stained sections (Fig. 2).
DNA was extracted using proteinase K and 5% Chelex resin. DNA
concentrations were measured using the Qubit 2.0 Fluorometer with
the Qubit dsDNA Assay Kit. Next generation sequencing (NGS) of tumor
and normal DNA was performed with a custom made primer panel
analyzed on an Ion Torrent S5XL-sequencer using suppliers' materials
and methods. The custom made primer panel (primer sequences
available upon request) was designed using Ion Ampliseq Designer
2.2.1. With this panel, libraries were created using the Ion AmpliSeq
Library Kit 2.0–384 LV. Template was prepared using the Ion Chef with
the Ion 520- and 530-kit chef. Sequencing was performed on an Ion 530
chip with the Ion PGM S5 Sequencing Kit. Data were analyzed with
Variant Caller v5.6. All products used were produced by Thermo Fisher
Scientiﬁc, Waltham, Massachusetts, United States of America.
2.4. Literature review
We searched Embase, Medline and Google Scholar for individuals
with FAMMM syndrome and esophageal cancer using “esophageal
cancer” and “familial multiple-mole melanoma syndrome” as keywords.
A detailed description of the search strategy and ﬂowchart is sum-
marized in Supplementary Figs. 1a and 1b.
3. Results
By genomic analysis, the previously identiﬁed germline variant in
CDKN2A exon 2 (p16-Leiden mutation, NM_000077.4: c.225_243del19
(p.p75fs) variant) was found in the esophageal tumors and in the
normal tissue of both patients (Fig. 3). This mutation variant was pre-
viously submitted in the ClinVar database with access number
VCV000182411. Via NGS, a variant allele frequency of 81% and 76%
was detected in the esophageal tumor for patient one and two, re-
spectively. In normal tissue, a variant allele frequency was detected of
54% and 64% for patient one and two, respectively. These results in-
dicate relative loss of the wildtype allele in both tumor DNA samples. In
addition, loss of heterozygosity (LOH) near and in the CDKN2A locus
was unambiguously demonstrated with NGS-based single-nucleotide
polymorphism (SNP) analysis in both patients (Fig. 4a–c) (Dubbink
et al., 2016). As depicted in Supplementary Fig. 1, two previous articles
described the presence of FAMMM patients with esophageal cancer
(Lynch et al., 2002; Middlebrooks et al., 2019).
Fig. 1b. Family tree of the second FAMMM patient in whom genomic LOH-analysis was performed (marked by an arrow) with two proven carriers of the p16-Leiden
variant in CDKN2A. Five individuals had clinical features of FAMMM in whom the mutation was not conﬁrmed.
Fig. 2. Hematoxylin and Eosin stainings for patient 2 both before (left) and after (right) microdissection. After pathological examination of these biopsies,
patient was diagnosed with squamous cell carcinoma of the esophagus.
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4. Discussion
To our knowledge, this is the ﬁrst report of FAMMM patients with
the p16-Leiden germline variant in CDKN2A, who developed ESCC. The
SNP analysis of both tumors indicated loss of the CDKN2A locus
(Dubbink et al., 2016). In addition, the variant allele frequency of the
CDKN2A germline mutation in both tumors (patient 1 and patient 2;
81% and 76%, respectively) indicated that this loss was of the wildtype
allele with conservation of the germline mutant CDKN2A allele. In both
tumors, obviously, biallelic inactivation of the CDKN2A gene occurred.
Fig. 3. Sequencing analysis of tumor tissue in patient 2. Sequencing analysis results on the Ion GeneStudio S5 PrimeTorrent Personal Genome Machine for
CDKN2A exon 2. Each horizontal line represents an individual read of diﬀerent copies of the ampliﬁed sequence; each pink read represents an individual forward
strand and each blue read represents an individual reverse strand. The black lines represent the deletions. The A, C, G and T represent the four nucleotides in the
sequence and the corresponding amino acids are noted underneath. The example in this ﬁgure clearly shows the p16-Leiden NM_000077.4: c.225_243del19 (p.p75fs)
variant.
Fig. 4a. Overview on possible locations after NGS-based variant allele frequency analysis. Explanatory ﬁgure showing the possible outcomes in NGS-based
variant allele frequency analysis. Ordinarily, the X-axis represents the location on the chromosome in million base pairs (Mbp) and the Y-axis represents the variant
allele frequency. A variant allele frequency between 0 and 5% indicates a homozygous wild-type allele since nearly no variant allele is detected; a variant allele
frequency between 95 and 100% indicates a homozygous mutation of both alleles since (nearly) all of the alleles are of the variant type. A variant allele frequency
between 45 and 55% indicates heterozygosity since roughly half of the alleles is of the variant type. A variant allele between 5 and 45% indicates that some of one
wild-type allele is lost and predominantly wild-type alleles are still present, a variant allele frequency between 55 and 95% indicates that some of the second wild-
type allele is also lost and predominantly the mutated allele is present.
B.J. van der Wilk, et al. European Journal of Medical Genetics xxx (xxxx) xxxx
4
Hence, these results strongly suggest that ESCC developed in the con-
text of FAMMM syndrome in both patients.
Pathogenic CDKN2A germline variants are associated with in-
creased risk for developing melanomas and pancreatic cancer. A study
with 19 families with a pathogenic CDKN2A germline variant showed a
wide diversity in cancer presentation, including three patients with
esophageal cancer. One had small cell carcinoma and two a malignancy
of unknown histology (Lynch et al., 2002). Another recent study also
reported that FAMMM patients with a pathogenic CDKN2A variant are
at increased risk for the early onset of several malignancies
(Middlebrooks et al., 2019). It was suggested that, besides melanomas
and pancreatic cancer, also a higher proportion of malignancies in the
colon, nervous system, soft tissue, bone, testis, ovary and esophagus
was present in mutation carriers versus non-carriers.
Fig. 4b. NGS-based variant allele frequency via SNP analysis in the ﬁrst patient. The X-axis shows the location on chromosome 9p in million base pairs (Mbp).
The Y-axis shows the percentage of variant allele frequency. LOH was unambiguously demonstrated on several locations of chromosome 9p near the CDKN2A locus of
the ﬁrst FAMMM patient.
Fig. 4c. Also in the second patient, LOH was unambiguously demonstrated on several locations of chromosome 9p both near and in the CDKN2A locus.
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CDKN2A mutations are reported in precancerous esophageal lesions
and the mutations can thus be an early event in the ESCC carcinogenesis
(Liu et al., 2017). Additionally, somatic inactivation of the CDKN2A
gene is frequently reported in sporadic ESCC patients, mostly via mu-
tations or epigenetic processes like promotor hypermethylation
(Abbaszadegan et al., 2005; N. Cancer Genome Atlas Research et al.,
2017). Several studies reported somatic (epigenetic) silencing of
CDKN2A in ESCC ranging from 25% to 76%; one of these studies found
biallelic inactivation in 13% of patients with ESCC (Hu et al., 2004).
This indicates that patients with a germline pathogenic CDKN2A var-
iant may be at higher risk of ESCC, but further studies are needed to
clarify the prevalence and clinical relevance of the combination.
Since tobacco use was reported to increase the risk for development
of several (squamous cell) cancers in FAMMM patients, one could not
rule out this had a synergistic eﬀect for development of the tumor in
one of our patients (Potjer et al., 2015). This underlines the need to
discourage carriers of a pathogenic CDKN2A variant not to smoke. Not
only to prevent lung, pancreatic and head and neck cancer, but also to
prevent esophageal cancer.
In conclusion, this study suggests that ESCC developed in the con-
text of FAMMM syndrome in the two presented patients and a relation
between CDKN2A and esophageal cancer is also supported by the cur-
rently available literature. Patients with a pathogenic germline variant
in CDKN2A may be at higher risk for developing ESCC and alertness for
clinical features of esophageal cancer should be warranted in these
patients. However, since earlier reports on ESCC with FAMMM are
scarce, future studies are needed to clarify both the prevalence and the
clinical relevance of this combination.
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